Cancer Treatment

Merkel cell carcinoma

4 min read
Image of lungs

Merkel Cell Carcinoma: A Comprehensive Guide to Diagnosis and Treatment

Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that typically appears as a painless, firm, and fast-growing lump on the skin. It is most commonly found on sun-exposed areas such as the face, neck, and limbs. MCC primarily affects older individuals with weakened immune systems, but it can also occur in younger individuals without any known risk factors.

Epidemiology of Merkel Cell Carcinoma

MCC is a relatively uncommon cancer, accounting for about 2% of all skin malignancies globally. The incidence of MCC has been steadily increasing over the past few decades, which is concerning. It is estimated that over 2,000 new cases of MCC are diagnosed each year in the United States alone.

The exact cause of MCC is still unknown. However, it has been strongly linked to a virus called Merkel cell polyomavirus (MCPyV). Other risk factors for MCC include excessive exposure to UV radiation, a weakened immune system due to conditions like organ transplantation or HIV/AIDS, and a history of other skin cancers.

Diagnosis of Merkel Cell Carcinoma

MCC can be challenging to diagnose as its early stages often mimic harmless skin conditions. Nevertheless, it is crucial to obtain an accurate diagnosis as early as possible to improve treatment outcomes. Dermatologists may conduct various tests and procedures to confirm MCC, including:

  • Skin biopsy to analyze the abnormal tissue
  • Immunohistochemistry to detect specific markers associated with MCC
  • Imaging tests, such as CT scans or PET scans, to determine the extent of the cancer

Treatment of Merkel Cell Carcinoma

The treatment approach for MCC depends on several factors, including the stage of the cancer, the patient's overall health, and the presence of metastasis. The main treatment options for MCC include:

  1. Surgery: The primary tumor is removed along with a margin of healthy tissue to ensure complete excision. In some cases, lymph nodes may also be removed if they are affected by cancer.
  2. Radiation Therapy: High-energy beams are targeted at the affected area to kill cancer cells and prevent their growth. It may be used as a standalone treatment or in combination with surgery.
  3. Chemotherapy: Drugs are administered either intravenously or orally to destroy cancer cells throughout the body. Chemotherapy is generally reserved for advanced or metastatic MCC.

Current Drugs Used in Merkel Cell Carcinoma Treatment

Several drugs have shown efficacy in treating MCC and are currently used in clinical practice. These include:

  • Keytruda (pembrolizumab): This immunotherapy drug has revolutionized the treatment of MCC by boosting the patient's immune system to recognize and attack cancer cells. It has shown impressive response rates, leading to its FDA approval for MCC treatment.
  • Avelumab: Another immunotherapy drug that targets the immune checkpoint pathway, enhancing the immune response against cancer cells. Avelumab has also been approved for the treatment of metastatic MCC.
  • Chemotherapy: Various chemotherapeutic agents, such as carboplatin and etoposide, are used in the systemic treatment of MCC. They work by preventing cancer cells from dividing and multiplying.

Promising Drugs in Late-Stage Clinical Trials

Researchers are actively investigating new drugs and treatment strategies to further improve outcomes for patients with MCC. Some promising drugs currently in late-stage clinical trials include:

  • Tilsotolimod (IMO-2125): This drug is an agonist of the innate immune receptor, Toll-like receptor 9 (TLR9). It activates the immune system to recognize and attack cancer cells specifically. Preliminary results have shown encouraging activity in advanced MCC.
  • Lenvatinib: An oral targeted therapy that inhibits multiple signaling pathways involved in tumor growth and progression. Initial studies have shown promising results, and further research is underway to evaluate its efficacy in MCC treatment.

In conclusion, Merkel cell carcinoma is a rare and aggressive form of skin cancer. Early diagnosis and appropriate treatment are crucial for improving outcomes. Current treatment options include surgery, radiation therapy, and chemotherapy. Exciting advancements have been made with the use of immunotherapy drugs such as Keytruda and Avelumab. Additionally, promising drugs like tilsotolimod and lenvatinib are being evaluated in late-stage clinical trials. Continued research and advancements in treatment strategies offer hope for improved outcomes for individuals diagnosed with Merkel cell carcinoma.